Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France

• Main Authors: Amy Lee (Author), Benjamin Davido (Author), Ekkehard Beck (Author), Clarisse Demont (Author), Keya Joshi (Author), Michele Kohli (Author), Michael Maschio (Author), Mathieu Uhart (Author), Nadia El Mouaddin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in Fall 2023 and Spring 2024 in France. The number of symptomatic SAR...